Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02841501
  4. Details
NCT02841501 Clinical Trial

Genetic Susceptibility Factors for Candidemia.

Genetic Predisposition to Disease Clinical Trial

Official title:
Genetic Susceptibility Factors Involved in Candidemia: Case-control Study.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02841501
Other study ID # 2011_63
Secondary ID 2012-A01344-39
Status Completed
Phase
First received
Last updated
Start date June 2013
Est. completion date June 25, 2020

Study information
Verified date August 2020
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective case-control physiopathological study, which main objective is to determine the genetic host factors predisposing to candidemia. Secondary objectives are to develop new diagnosis tools using the biological collection, to describe and update epidemiology, to analyse the influence of genetic polymorphisms on prognosis.

Recruitment information / eligibility
Status Completed
Enrollment 453
Est. completion date June 25, 2020
Est. primary completion date June 25, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient older than 18 years. - Informed consent. - Positive blood culture with isolation of Candida sp. Exclusion Criteria: - No informed consent. - Patient younger than 18. - No insurance coverage.

Study Design

Related Conditions & MeSH terms

Intervention

Genetic:
• Analysis of genetic polymorphisms
An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.

Locations
Country Name City State
France Hôpital Salengro, Intensive care departement, CHRU Lille

Sponsors (3)
Lead Sponsor Collaborator
University Hospital, Lille Seventh Framework Programme, University of Lausanne Hospitals

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Frequency of the polymorphisms between the groups In the 48-72 hours following the positive blood culture
See also
  Status Clinical Trial Phase
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Recruiting NCT06057181 - Helix Research Network
Recruiting NCT04390269 - Immunogenetics Predictors With COVID-19
Recruiting NCT04427163 - Assesment of Multiomics Profiles in Health and Disease.
Completed NCT03597659 - PheWAS of a Polygenic Predictor of Thyroid Function
Active, not recruiting NCT04634032 - Gene Expression and DNA Variation Analysis of Sacs to Identify the Pathophysiology of Indirect Inguinal Hernia
Completed NCT04145817 - Breast Cancer Risk After Diagnostic Gene Sequencing N/A
Recruiting NCT04600544 - Russian Disc Degeneration Study
Not yet recruiting NCT04788927 - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Not yet recruiting NCT03234140 - Constitutional Genetics in Follicular Lymphoma N/A
Completed NCT01973075 - Genetic Etiology in Premature Ovarian Insufficiency N/A
Completed NCT00555503 - Registry of Mastectomy for Breast Cancer Risk Reduction N/A
Active, not recruiting NCT05524909 - Full-scale Intervention Study: Genetic Risk Communication and Wearables N/A
Suspended NCT04151368 - Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy N/A
Completed NCT02422511 - Genomic Sequencing for Childhood Risk and Newborn Illness N/A
Completed NCT00677495 - Gluten-free Diet in Gluten-genetically Predisposed Subjects N/A
Recruiting NCT05759143 - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing N/A
Enrolling by invitation NCT05721326 - Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition N/A
Active, not recruiting NCT05685810 - Genetic Determinants of Kidney Disease in People of African Ancestry With HIV
Recruiting NCT04903782 - Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer